RE:NGM NASH drug bites the dustMDGL's CFO told me a while back that he viewed NGM as the biggest threat to them in NASH. So, I am surprised to see them fail so completely. It is both a positive and a negative for TH. Positive in that another NASH competitor bites the dust, negative in that it makes spending a huge sum of money on a phase III test seem even more daunting.
bfw wrote: These results are certainly disappointing, particularly given the dire unmet need in this patient population. The lack of significant fibrosis improvement was unexpected given the consistency of histology findings previously seen with aldafermin in our adaptive four-cohort Phase 2 study,” said David J. Woodhouse, Ph.D., Chief Executive Officer at NGM. “However, in line with the data from that study, ALPINE 2/3 achieved statistical significance on multiple non-invasive measures of NASH at the two higher doses. That said, given the failure to meet the primary endpoint, we have decided to shift resources that had previously been reserved for a Phase 3 F2/F3 NASH development program toward advancing our other programs.”